Ghisallo Capital Management’s Novavax NVAX Stock Holding History

Ghisallo Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-850,000	Closed	-$8.74M	–	91
2022 Q4	$8.74M	Buy	+850,000	New	+$15M	1.56%	14

Other funds holding NVAX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ghisallo Capital Management's NVAX Position: Q1 2023 in Review

Ghisallo Capital Management sold out of Novavax (NVAX) in Q1 2023, closing a stake of 850,000 shares — an estimated $8.74M sold.

Ghisallo Capital Management first reported a position in NVAX in Q4 2022 and held it in 1 quarter. The position peaked at $8.74M in Q4 2022. 222 funds tracked by Wall St. Rank hold NVAX as of Q1 2023.

Ghisallo Capital Management reported no remaining Novavax position as of Q1 2023 after selling out during the quarter.
Ghisallo Capital Management sold 850,000 Novavax shares in Q1 2023, an estimated $8.74M.
Ghisallo Capital Management first reported a position in Novavax in Q4 2022 and held it in 1 quarter.
Ghisallo Capital Management's Novavax position peaked at $8.74M in Q4 2022.
222 funds tracked by Wall St. Rank held Novavax as of Q1 2023.

Based on Ghisallo Capital Management's 13F filing for Q1 2023, filed 15 May 2023.